Jade Biosciences

Jade Biosciences is a clinical-stage biotechnology company developing monoclonal antibody therapies for serious autoimmune diseases. Its stated aim is to target upstream drivers of disease with the goal of maximizing clinical activity and enabling patient-friendly, infrequent subcutaneous dosing. The company says it pursues disease-driving biology where targeted intervention may meaningfully improve outcomes for patients.

The lead program, JADE101, is an anti-APRIL monoclonal antibody being developed for immunoglobulin A nephropathy (IgAN), a progressive autoimmune kidney disease. Jade describes the candidate as designed to bind APRIL at a novel epitope, with a half-life-extending modification intended to support durable exposure and a longer dosing interval. The company’s pipeline page lists JADE101 in Phase 2.

JADE201 is an anti-BAFF-R monoclonal antibody in development for autoimmune diseases. Jade describes it as designed to combine B-cell depletion with blocking BAFF signaling, which it says may help address the return of autoreactive B cells after treatment. The pipeline page lists JADE201 in Phase 1 and identifies multiple systemic autoimmune diseases as potential indications.

JADE301 is an anti-IFN-β monoclonal antibody in preclinical development for dermatomyositis, a rare autoimmune disease. Jade says the candidate is designed to selectively neutralize IFN-β and incorporates a half-life-extending modification, with the intended aim of supporting durable exposure and infrequent subcutaneous dosing. The company reports exclusive license agreements with Paragon Therapeutics for JADE101, JADE201, and JADE301.

Jade was launched on antibody candidates licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. A company filing states that Jade was established and incorporated in Delaware on June 18, 2024, and that Fairmount founded the company. Jade describes its team as bringing experience across drug development, from target selection through commercial launch.

The company’s stated mission is to act with urgency to bring life-changing, disease-modifying therapies to people with autoimmune disease, with the goal of making clinical remission possible. Its careers page describes a team centered on scientific bravery, shared accountability, and a service mindset that keeps patients at the center of decisions. These are company-stated goals and values, not claims about approved medicines; the programs described remain in clinical or preclinical development.